Calbindin S100A16 Promotes Renal Cell Carcinoma Progression and Angiogenesis via the VEGF/VEGFR2 Signaling Pathway

<div>Prognoses of S100A16 and patients with RCC in the TCGA database. (a). Low S100A16 expression was associated with improved OS, DSS, and PFI in the patients. (b). Stratified subgroup analysis revealed that the prognosis for individuals with low S100A16 expression was more favorable.</div>

Contrast Media & Molecular Imaging

fig3

Figure 3

Figure 3: Calbindin S100A16 Promotes Renal Cell Carcinoma Progression and Angiogenesis via the VEGF/VEGFR2 Signaling Pathway 